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Innate immune activating ligand 
SUMOylation affects tumor cell 
recognition by NK cells
Beatrice Zitti1, Rosa Molfetta1, Cinzia Fionda1, Linda Quatrini1,6, Helena Stabile1, Mario 
Lecce1, Valeria de Turris2, Maria Rosaria Ricciardi  3, Maria Teresa Petrucci4, Marco Cippitelli1, 
Angela Gismondi1, Angela Santoni1,5 & Rossella Paolini1
Natural Killer cells are innate lymphocytes involved in tumor immunosurveillance. They express 
activating receptors able to recognize self-molecules poorly expressed on healthy cells but up-regulated 
upon stress conditions, including transformation. Regulation of ligand expression in tumor cells mainly 
relays on transcriptional mechanisms, while the involvement of ubiquitin or ubiquitin-like modifiers 
remains largely unexplored. Here, we focused on the SUMO pathway and demonstrated that the ligand 
of DNAM1 activating receptor, PVR, undergoes SUMOylation in multiple myeloma. Concurrently, we 
found that PVR is preferentially located in intracellular compartments in human multiple myeloma cell 
lines and malignant plasma cells and that inhibition of the SUMO pathway promotes its translocation to 
the cell surface, increasing tumor cell susceptibility to NK cell-mediated cytolysis. Our findings provide 
the first evidence of an innate immune activating ligand regulated by SUMOylation, and confer to this 
modification a novel role in impairing recognition and killing of tumor cells.
Natural Killer (NK) cells represent a subset of innate lymphocytes largely involved in tumor immunosurveillance 
because of their ability to recognize and kill transformed cells and to secrete cytokines and chemokines1, 2. Their 
activation is controlled by the integration of signals induced by inhibitory receptors, which recognize Major 
Histocompatibility Complex (MHC) class I molecules on healthy cells, and activating receptors able to bind lig-
ands up-regulated in stressed cells3.
Therefore, understanding the molecular mechanisms underlying the expression of NK cell activating ligands 
on tumor cells is crucial for the development of new therapeutic anti-cancer approaches aimed at improving NK 
cell-mediated tumor clearance.
Several lines of evidence4–8 have reported a pivotal role for NK cells in controlling the progression of Multiple 
Myeloma (MM), an incurable age-dependent haematological neoplasia characterized by abnormal proliferation 
of malignant plasma cells (PCs) in the bone marrow (BM), associated with serum monoclonal gammopathy, bone 
destruction, and several organ dysfunctions9–11. Indeed, NK cells increase in number at the initial stages of the 
MM disease contributing to limit malignant PC expansion, while tumor progression is associated with a decline 
of NK cell surveillance4–8.
Different activating receptors are involved in NK cell-mediated MM cell recognition and elimination, after 
engaging of their ligands12–14. In particular, several studies have demonstrated that the interaction of the acti-
vating NK cell receptor DNAX accessory molecule 1 (DNAM1/CD226) with its ligands, Nectin2 (CD112) and 
Poliovirus Receptor (PVR/CD155)15, 16, contributes to the killing of MM cells13, 14. Moreover, a pivotal role played 
by DNAM1 in the control of tumor growth was reported in an in vivo model of spontaneous MM progression15, 17.
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Although expressed on normal cells including neuronal, epithelial, endothelial and fibroblastic cells, 
Nectin2 and PVR are found up-regulated on tumor cells14, 18–21. Several studies have documented transcrip-
tional regulation of DNAM1 ligand expression in response to different stimuli14, 22–25, while the involvement of 
post-translational mechanisms has been poorly investigated so far.
We focused on the SUMO pathway, an emerging post-translational modification that was found deregulated 
in many tumors, including breast and lung cancer, glioblastoma and MM26–28. It is catalyzed by the sequential 
action of three classes of enzymes, namely E1, E2 and E3, and culminates in the covalent addition of a member of 
the SUMO (small ubiquitin-like modifier) protein family to lysine residues of specific targets29, 30. SUMO modi-
fication leads to different outcomes: it can affect the enzymatic activity of target proteins, their ability to interact 
with other macromolecules as well as their subcellular localization29, 30.
It is well documented that under stress conditions, including malignant transformation, a general increase 
in protein SUMO conjugation occurs30, often as a result of the E2 SUMO conjugating enzyme UBC9 overex-
pression26–28, 31, 32. In particular, overexpression of UBC9 and of other SUMO pathway components in MM cells 
correlates with poor prognosis28. However, whether the SUMO pathway affects tumor recognition by immune 
cells is currently unknown.
To gain insight into this issue we investigated whether the SUMO pathway regulates PVR and Nectin2 expres-
sion on MM cells.
Here, we show that both DNAM1 ligands are expressed in MM cell lines and patient’s derived malignant 
plasma cells (PC), and preferentially localized in intracellular compartments. The SUMO pathway controls PVR, 
but not Nectin2 surface expression. PVR is directly subjected to SUMOylation and this modification prevents its 
surface expression impairing DNAM1-mediated NK cell recognition.
We have also provided evidence that the SUMO pathway regulates PVR surface expression in tumors other 
than MM, supporting a more general role for this modification in regulating tumor cell susceptibility to NK 
cell-mediated cytotoxicity.
These data reveal a previously unknown role for the SUMO pathway and provide novel insights in molecular 
mechanisms underlying expression of innate immune activating ligands on tumor cells.
Results
The SUMO pathway regulates PVR but not Nectin2 cell surface expression in MM cells. To 
investigate whether post-translational mechanisms are involved in PVR and Nectin2 expression in MM cells, 
we initially evaluated surface and total (surface plus intracellular) protein levels by immunofluorescence and 
FACS analysis on malignant PCs derived from MM patients at different clinical stages (Supplementary Table 1) 
before and after cell permeabilization, respectively. After excluding doublets, the analysis was restricted to 
CD38+CD138+ malignant PCs (Supplementary Fig. S1a). PVR and Nectin2 protein expression was always much 
higher upon cell permeabilization with respect to unpermeabilized cells (Fig. 1a), independently from the clin-
ical stage of the disease (Supplementary Fig. S1b). These results indicate that a pool of both proteins is present 
in intracellular compartments. As negative control, we verified that circulating B cells from healthy donors are 
negative for both surface and total DNAM1 ligand expression (data not shown).
Next, we analysed a panel of human MM cell lines and demonstrated that total expression levels of both PVR 
and Nectin2 were higher than their surface levels in the vast majority of them (Fig. 1b).
Altogether, these results suggest the involvement of post-translational mechanisms in the regulation of PVR 
and Nectin2 surface expression.
To investigate whether the SUMO pathway could be responsible for the intracellular retention of PVR and 
Nectin2 in MM cells, we took advantage of the use of Ginkgolic Acid (GA), an inhibitor of SAE1/UBA2, the E1 
enzyme responsible for SUMO modification33.
ARK and OPM2 cell lines were treated overnight with GA, and the treatment efficacy was verified by means 
of a reduced amount of SUMOylated proteins on cell lysates (Fig. 2a). Upon GA treatment, we found that PVR 
surface expression was enhanced in both cell lines (Fig. 2b and c, upper panels), while the expression of Nectin2 
(Fig. 2b and c, lower panels) and that of MHC-I used as negative control (data not shown) remained unaffected.
To further confirm these data with a different approach, we stably infected ARK and OPM2 cells lines with 
a lentiviral vector carrying a shRNA that targets the E2 SUMO conjugating enzyme UBC934. Although we only 
obtained around 40% of UBC9 protein reduction (Fig. 2d), UBC9 knockdown resulted in an increased of PVR 
but not Nectin2 surface expression in both ARK and OPM2 cell lines (Fig. 2e and f), confirming the results 
obtained upon GA treatment.
We then analysed the involvement of SUMO pathway in the regulation of PVR expression on patient malig-
nant PCs. Upon GA treatment, we observed a significant and reproducible increase in PVR but not Nectin2 
surface expression in most of the MM patients analysed (Fig. 3a and b).
Altogether these results support the conclusion that the SUMO pathway regulates PVR expression in MM 
cells.
PVR is a target of SUMOylation. To elucidate if PVR can be directly modified by SUMO, we performed 
an in vitro SUMOylation assay by using as a substrate a human recombinant full-length form of PVR. The addi-
tion of ATP in the presence of SUMO1 protein and the enzymes involved in the reaction, promoted the appear-
ance of SUMO1 conjugates of high molecular weight (MW) that are specifically recognized by anti-SUMO1 
antibody, indicating that PVR can be subjected to SUMOylation (Fig. 4a).
To further investigate whether PVR undergoes SUMOylation in MM cells, PVR was immunoprecipitated 
from lysates of ARK cells treated or not with GA (Fig. 4b). In untreated cells, anti-SUMO1 immunoblot revealed 
the presence of several bands of high MW that disappeared upon GA treatment, suggesting that they correspond 
to SUMOylated PVR species.
www.nature.com/scientificreports/
3SCientifiC RePoRtS | 7: 10445  | DOI:10.1038/s41598-017-10403-0
To formally demonstrate that PVR is directly SUMOylated in MM cells, we exploited the approach of 
Proximity Ligation Assay (PLA) that allows in situ detection of protein interactions and modifications with high 
specificity and sensitivity; ARK cells were incubated with anti-SUMO1 alone (as negative control) or in combi-
nation with anti-PVR, processed following PLA protocol, and analysed by confocal microscopy. We detected 
specific green fluorescent spots only in ARK cells stained with both anti-PVR and anti-SUMO1 antibodies, 
demonstrating that PVR directly interacts with SUMO1 (Fig. 4c, middle panel). The same PLA reaction per-
formed in a different cell line (ARP) that does not express PVR (see Fig. 1b), did not generate any significant fluo-
rescent spots (Fig. 4c, right panel), confirming the specificity of this assay. A 3D reconstruction of all optical slices 
acquired along z-axis (Supplementary Multimedia File 1) confirmed the cytoplasmic localization of PLA spots.
PLA assay was also carried out on ARK cells stably transfected with UBC9-shRNA or with Ctrl-shRNA 
(Mock). We observed a significant reduction of PLA spots upon UBC9 silencing (Fig. 4d), as confirmed by quan-
tification analysis, indicating that the inhibition of SUMO pathway strongly decreases the amount of SUMOylated 
PVR.
Altogether our data demonstrate that PVR undergoes SUMOylation in MM cells.
SUMOylation of PVR controls its subcellular localization. To investigate the role of PVR 
SUMOylation, surface and total PVR protein expression was initially analysed by flow cytometry before and after 
inhibition of the SUMO pathway. Upon UBC9 silencing (Fig. 5a) or GA treatment (Fig. S2a), we observed that the 
total protein expression of PVR remains unaffected compared to control cells, despite the increase of protein lev-
els at the cell surface. As expected, quantitative real time PCR performed on ARK cells revealed that PVR mRNA 
amount does not change in UBC9 silenced cells respect to control samples (Fig. 5b), thus excluding a regulation 
occurring at transcriptional level. Similar results were obtained upon GA treatment (Fig. S2b).
Finally, we analysed PVR subcellular localization by confocal microscopy. We observed that PVR is mainly 
distributed throughout the cytoplasm in control cells, while it is preferentially localized at the plasma membrane 
upon inhibition of the SUMO pathway (Figs 5c and S2c).
Altogether these results demonstrate that the inhibition of the SUMO pathway promotes the redistribution of 
the intracellular pool of PVR, resulting in its up-regulation on the cell surface without any effect on total protein 
expression.
Figure 1. PVR and Nectin2 are mainly found as intracellular pool in MM cells. (a) CD38+ CD138+ malignant 
PCs derived from BM aspirates of MM patients (n = 34) were analysed for PVR and Nectin2 surface and 
total (surface plus intracellular) expression before and after fixation and permeabilization, respectively. Cells 
were acquired using FACSCanto flow cytometer (BD Biosciences). Each dot represents a single patient, 
****p < 0.001, Wilcoxon matched pairs test. (b) PVR (left panel) and Nectin2 (right panel) surface and 
total (surface plus intracellular) expression was analysed on MM cell lines before and after fixation and 
permeabilization, respectively. Cells were acquired using FACSCalibur flow cytometer (BD Biosciences). Data 
represent the means ± SD of PVR and Nectin2 from three independent experiments. *p < 0.05, Student T test. 
MFI: mean fluorescence intensity.
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Inhibition of the SUMO pathway increases MM susceptibility to NK cell mediated lysis. To 
investigate whether the inhibition of the SUMO pathway affects MM susceptibility to NK cell-mediated kill-
ing, we performed a cytotoxicity assay in which primary cultured human NK cells were used as effector cells. 
UBC9-silenced ARK cells were lysed more efficiently respect to control cells at all effector:target (E:T) ratios 
analysed (Fig. 6a). Moreover, we observed that in the presence of anti-DNAM1 blocking antibody NK cell cyto-
toxicity towards UBC9 silenced target cells is more extensively inhibited compared to Mock target cells (45% and 
25% of inhibition, respectively), strongly suggesting that PVR surface up-regulation contributes to the increased 
susceptibility to NK cell lysis. Similar results were obtained using as targets GA-treated ARK cells (Fig. S2d) but 
not GA-treated LP1 cells (Fig. S2e), a MM cell line that does not show PVR intracellular retention (see Fig. 1b).
Inhibition of the SUMO pathway also resulted in enhanced ability of MM cells to stimulate NK cell degranula-
tion measured by means of membrane expression of the cytotoxic granule marker CD107a (Fig. 6b).
The partial inhibition of both cytotoxicity and degranulation observed in the presence of anti-DNAM1 block-
ing antibody may be explained by the involvement of a receptor other than DNAM1.
Besides DNAM1, a major role for NKG2D activating receptor on MM cell killing has been also established13, 14. 
However, a contribution of NKG2D/NKG2D ligand axis in our experimental setting can be excluded since 
ARK cells do not express the NKG2D ligands MIC and ULBP, before and after inhibition of SUMOylation 
(Supplementary Fig. S3).
It has been shown that DNAM1 activation requires the association with the adhesion molecule LFA135, there-
fore we checked the expression levels of the LFA1 ligand, ICAM1, on MM cells. Upon inhibition of the SUMO 
pathway, FACS analysis demonstrated that ICAM1 expression was not significantly affected compared to control 
cells (Fig. 6c), excluding the possibility that the enhanced NK cell degranulation and killing may depend on an 
Figure 2. SUMOylation controls PVR but not Nectin2 surface expression in MM cell lines. (a–c) Inhibition 
of the SUMO pathway was achieved by means of overnight treatment with 25μg/mL Ginkgolic Acid (GA). 
The efficacy of treatment was verified by means of western blot analysis on total cell lysates (a). (b,c) PVR and 
Nectin2 surface expression was evaluated on ARK and OPM2 cell lines by immunofluorescence and FACS 
analysis using FACSCalibur flow cytometer (BD Biosciences). One out of three independent experiments (b) 
and means ± SD of PVR and Nectin2 MFI from three independent experiments (c) are shown. **p < 0.01, 
***p < 0.001, Two-way ANOVA. (d–f) Inhibition of the SUMO pathway was achieved by means of UBC9 
gene silencing. Silencing efficiency was verified by means of western blot analysis on total cell lysates (d). (e,f) 
PVR and Nectin2 surface expression was evaluated on ARK and OPM2 cell lines by immunofluorescence and 
FACS analysis using FACSCanto flow cytometer (BD Biosciences). One out of three independent experiments 
(e) and means ± SD of PVR and Nectin2 MFI from three independent experiments (f) are shown. **p < 0.01, 
***p < 0.001, Two-way ANOVA.
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increased LFA1/ICAM1 interaction. Moreover, we found that the number of conjugates between NK and ARK 
cells before and after UBC9 silencing does not change in the same experimental setting (Fig. 6d).
Altogether these results support the conclusion that the enhanced susceptibility to NK cell killing mostly 
depends on the increased surface expression of PVR.
Accordingly, highly purified patient derived CD138+ PCs treated with GA induced a higher extent of autolo-
gous BM-derived NK cell degranulation compared to vehicle-treated cells (Fig. 7a). Noteworthy, the fold induc-
tion of NK cell degranulation directly correlated with the increase of PVR surface expression on CD138+ MM 
cells (Fig. 7b).
Collectively, our data demonstrate that PVR SUMOylation impairs the ability of NK cells to recognize and kill 
MM cells in a DNAM1-dependent manner.
PVR SUMOylation affects susceptibility to NK cell lysis in tumors different from 
MM. Up-regulation of the SUMO pathway is a common feature of several types of cancer26, 27, thus we decided 
to extend our analysis on other high malignant tumors.
We focused our attention on MDAMB231 breast cancer and U87MG glioma cell lines, and we first analysed 
whether the SUMO pathway regulates PVR surface expression. Despite a high basal level of ligand expression, 
the GA treatment resulted in a slight but reproducible up-regulation of PVR membrane expression on both cell 
lines (Fig. 8a) and rendered them more susceptible to DNAM1-mediated NK cell cytotoxicity (Fig. 8b). We 
have then evaluated PVR SUMOylation status by performing PLA reaction. Fluorescent spots corresponding to 
PVR-SUMO interaction only appeared in the presence of anti-SUMO1 and anti-PVR specific antibodies and not 
in negative control reactions (Fig. 8c), indicating that PVR undergoes SUMOylation.
These results demonstrate that PVR expression can be regulated by the SUMO pathway also in tumors other 
than MM, and suggest that PVR SUMOylation represents a more general strategy to prevent DNAM1-dependent 
tumor cell recognition and killing by NK cells.
Discussion
MM is a still incurable neoplastic disease and represents the 13% of all haematological malignancies10, 11. Among 
currently used therapeutic strategies, immunomodulatory drugs have recently been proven to successfully poten-
tiate the ability of immune cells, including NK cells, to fight tumor spreading36, 37. During tumor progression, 
MM cells produce immune suppressive factors and reduce surface expression of ligands for NK cell activating 
receptors12, 38, thus rendering NK cells progressively unable to efficiently counteract malignant PC expansion4–6. 
In this context, it is still currently unknown whether post-translational modifications regulate the expression of 
these ligands on MM cells thus affecting their susceptibility to NK cell-mediated killing.
Figure 3. Ginkgolic Acid treatment up-regulates PVR but not Nectin2 surface expression in malignant PCs. 
Malignant PCs were treated overnight with 25 μg/mL of GA or vehicle alone (DMSO), and PVR (a) and Nectin2 
(b) surface expression was evaluated on cells gated as in Supplementary Fig. 1a. Data from two representative 
patients are shown in left panels. Data from 9 patients analysed are shown in right panels. Each dot represents a 
single patient. ***p < 0.001 Wilcoxon matched pairs test.
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Here, we show that the surface expression of a ligand for the activating receptor DNAM1, PVR, is regulated 
at post-translational level in MM cells. In particular, our major findings were: (1) PVR undergoes SUMOylation 
in MM cells; (2) SUMOylated PVR is retained intracellularly; (3) SUMOylation of PVR, by preventing its surface 
expression, impairs NK cell-mediated MM surveillance.
SUMO conjugation to protein substrates is frequently up-regulated during tumor transformation, and the 
function of SUMOylated proteins has been extensively studied in the context of nuclear-associated processes, such 
Figure 4. PVR undergoes SUMOylation in MM cells. (a) Human recombinant full length PVR was used as 
substrate for in vitro SUMOylation assay. The reaction was carried out in the presence (+) or in the absence 
(−) of ATP. The presence of modified PVR species was evaluated by western blot analysis using anti-SUMO1 
(Y299) and anti-PVR (S-18) Abs. (b) ARK cells were treated (+) or not (−) over-night with 25 μg/mL of GA, 
and then lysed. Cell lysates were immunoprecipitated with anti-PVR (SKII.4) or with an isotype-matched Ab 
(Ctrl Ig). Immunoprecipitated proteins were split and separated in two SDS/PAGE, transferred on nitrocellulose 
filters, and immunoblotted as indicated. (c) Proximity ligation assay (PLA) was performed on ARK and ARP 
cell lines. Anti-PVR (D171) and anti-SUMO1 (BML-PW9460) were used as primary Abs, as indicated. Positive 
PLA signals are visualized as green fluorescent spots, nuclei are in blue (DAPI). Images are representative of 
three independent experiments, and were acquired with zoom 2 using 60X/1.35NA oil immersion objective. 
Z-projections of 40 slices are shown. (d) Proximity ligation assay was performed and analysed as in Fig. 4c on 
UBC9-silenced or Mock infected ARK cells (left panels). Number of spots per cell was quantified using Fiji 
ImageJ Software (right panel). Data represent the means ± SD of three independent experiments. **p < 0.01, 
Student T test.
www.nature.com/scientificreports/
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as transcriptional regulation, chromatin remodelling, DNA repair, telomere maintenance, nucleo-cytoplasmic 
transport, and mitosis29, 30. More recently, a role for SUMOylation in the regulation of membrane protein expres-
sion and/or function was also becoming clear. SUMOylation regulates the expression and function of glucose 
transporters39 and the expression of the mutated cystic fibrosis transmembrane conductance regulator in cystic 
fibrosis40. Moreover, in the case of kainate receptors, the voltage-gated potassium channels and the transforming 
growth factor β receptor (TGFβR), SUMO conjugation directly regulates receptor activity41–43. Notably, in neu-
rons, SUMOylation of the kainate receptor subunit GluR6 increases ligand-induced receptor endocytosis42.
Our findings provide the first evidence of a ligand of NK cell activating receptors that is regulated by the 
SUMO pathway.
Indeed, we demonstrate that PVR is subjected to SUMOylation in MM cells likely as a consequence of the 
up-regulation of the SUMO pathway that occurs during transformation28. Although we were unable to quantify 
the amount of PVR that is modified by SUMO, it is well established that SUMO modification of a small substrate 
population is sufficient to elicit a functional consequence29.
Concurrently, we found that PVR is preferentially located in intracellular compartments both in MM cell lines 
and PCs derived from MM patients, and that inhibition of the SUMO pathway promotes PVR translocation to 
the cell surface. These observations strongly suggest that SUMOylation of PVR is responsible for its intracellular 
localization contributing to tumor evasion. Whether SUMOylation of PVR prevents its membrane localization or 
promotes its constitutive internalization is currently unclear.
Figure 5. PVR subcellular localization is controlled by SUMOylation. (a) PVR surface and total expression 
was analysed on ARK cells upon UBC9 gene silencing as in Fig. 1b. Cells were acquired using FACSCanto 
flow cytometer. Data represent the means ± SD of three independent experiments. **p < 0.005, Two-way RM 
ANOVA. (b) Total RNA, extracted from Mock or UBC9 silenced ARK cells (shUBC9) was used for cDNA 
first-strand synthesis, and Real-time polymerase chain reaction for PVR mRNA was performed using the ABI 
Prism 7900 Sequence Detection system. Relative mRNA amount, normalized with GAPDH, was expressed 
as arbitrary units and referred to mock-transfected cells, considered as calibrator. Means ± SD of three 
independent experiments are shown. (c) Mock infected and UBC9-silenced ARK cells were stained with anti-
PVR mAb (clone D171) followed by Alexa 488-conjugated goat anti-mouse Ab and counterstained with DAPI. 
Fluorescence and Differential Interference Contrast images were acquired with zoom3 using 60X/1.35NA oil 
immersion objective. A single optical slice (left panels) and a plot of pixel intensity of PVR signal along a section 
of interest (right panels) are shown.
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We observed that the PVR intracellular localization as well as protein surface expression in PCs derived from 
MM patients is independent from the clinical stage. This result is compatible with the murine model of MM in 
which PVR expression does not change during MM progression17. We speculate that during tumor transfor-
mation stressful events such as DNA damage, in addition to promote transcriptional PVR expression14, 22–25, 
up-regulate the SUMO pathway that in turn prevents surface PVR expression during MM progression.
Along with PVR, we found that the other DNAM1 ligand, Nectin2, is also prevalently expressed as intracellu-
lar pool. However, Nectin2 surface expression is not regulated by SUMO pathway, suggesting the involvement of 
post-translational modifications different than SUMOylation. To this regard, our preliminary observations indi-
cate that Nectin2 undergoes ubiquitination (Zitti et al. unpublished observations). Thus, it is likely that more than 
one post-translational modification could cooperate to regulate DNAM1 ligand surface expression. Experiments 
are currently ongoing to further explore this possibility.
The functional consequence of the increased PVR surface expression is the improvement of MM susceptibil-
ity to NK cell-mediated killing. Even though we found that the SUMO pathway regulates PVR but not Nectin2 
expression, it is likely that the up-regulation of PVR expression is sufficient to affect MM susceptibility to NK 
cell-mediated lysis. Indeed, PVR was found to bind to DNAM1 with a higher affinity than Nectin244.
Although an indispensable role for DNAM1 is envisaged by its contribution to NK cell-mediated MM 
immune surveillance in vivo17, we cannot rule out that the expression of NK cell activating ligands different than 
PVR can be also modulated by SUMO pathway.
Regarding receptors that are implicated in MM cell recognition12–14, we have excluded the contribution of 
NKG2D/NKG2D ligand axis in our experimental setting. Of note, the requirement of DNAM1-PVR interaction 
Figure 6. Inhibition of PVR SUMOylation increases MM cell susceptibility to NK cell mediated lysis. Primary 
cultured NK cells were pre-treated for 20 minutes at RT with anti-DNAM1 neutralizing mAb or with anti-CD56 
(Ctrl mAb) and were used as effector cells in a 4 hours 51Cr release assay (a) or in a CD107a degranulation assay 
(b) toward shUBC9 infected or mock infected cells. (a) NK cells were incubated with target cells at the indicated 
E:T ratios. The percentage of specific lysis (left panel) and Lytic Units (right panel), calculated as described in 
Materials and Methods, from three independent experiments (mean ± SD) are shown. *p < 0.05, **p < 0.01, 
One-way ANOVA. (b) After 4 hours of co-culture cells were stained with CD107a-APC, CD56-PE, CD3-
FITC and CD138-PerCP-CY5.5 to gate the CD56+ CD3− CD138− NK cell population, and the analysis was 
performed with FACSCanto (BD Biosciences). Left panels: the percentage of CD107a+ NK cells is shown and is 
representative of three independent experiments. Right panel: Means ± SD of three independent experiments 
are shown. *p < 0.05, **p < 0.01, Two-way ANOVA. (c) ICAM1 expression on UBC9 silenced or Mock infected 
ARK cells was measured by immunofluorescence and FACS analysis. One representative experiment out of 
three is shown. (d) Primary cultured NK cells were labelled with CellTracker Deep Red (TermoFisher), and 
then let to interact for 30 minutes with Mock infected or UBC9 silenced ARK cells labelled with CFSE. The 
percentage of the double positive cells is shown.
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appears to be particularly relevant when tumor cells lack the expression of other NK cell-activating ligands45, as 
happens in advanced MM stages during which NKG2D ligands are down-modulated12, 38.
In addition, we have also excluded (data not shown) the involvement of the SUMO pathway in the surface 
expression regulation of CS1 (CD2 subset 1), a surface molecule of the SLAM family highly expressed on MM 
cells that represents a promising target for the treatment of MM46.
Several reports have demonstrated transcriptional induction of DNAM1 ligands in tumor cells including MM, 
and some of the transcription factors involved have been recently identified22–25, 37.
Our data add a new level of complexity, supporting a role for post-translational mechanisms in the regulation 
of PVR expression. Indeed, we demonstrate that PVR itself undergoes SUMOylation and that this pathway regu-
lates PVR expression without affecting its mRNA and protein levels.
Previous results demonstrated that chemotherapeutic drugs including melphalan, doxorubicin and borte-
zomib, increase DNAM1 ligand expression on MM cells14, 47 acting at transcriptional level through the activation 
of different signaling pathways. Whether those chemotherapeutic drugs can also affect PVR expression through 
the regulation of the SUMO pathway is currently unknown.
It is interesting to point out that we have provided results demonstrating that the SUMO pathway regulates 
PVR expression in tumors other than MM, suggesting that PVR SUMOylation is a more general strategy to pre-
vent DNAM1-dependent recognition and killing by NK cells.
A post-translational mechanism to repress surface expression of DNAM1 ligands was also reported in 
hepatocellular carcinoma48 and upon Cytomegalovirus (CMV) infection49, 50. The activation of Unfolded 
Protein Response (UPR) resulted in down-regulation of PVR surface expression by protein degradation in 
Figure 7. Inhibition of PVR SUMOylation in patient-derived malignant PCs enhances autologous NK cell 
degranulation. NK cells derived from BM aspirates of MM patients were used as effector cells in a CD107a 
degranulation assay toward CD38+ CD138+ autologous MM cells treated overnight with GA or vehicle 
alone (DMSO). After 2 hours of co-culture cells were stained and analysed as in Fig. 6b. (a) Data from three 
representative patients are shown. (b) Correlation between PVR fold increase on MM cells and fold increase of 
NK cell autologous degranulation is shown (R = 0.83; p < 0.05).
www.nature.com/scientificreports/
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hepatocellular carcinoma, while upon CMV infection an immature form of PVR is retained in ER by the viral 
protein UL141. The same protein is also responsible for Nectin2 constitutive degradation50. These results suggest 
that post-translational regulation of DNAM1 ligand expression represents a common mechanism to evade NK 
cell recognition both in transformed and infected cells.
In line with these results, the expression of the murine ligand for NKG2D receptor Mult1 is prevented by a 
constitutive protein ubiquitination and degradation51, suggesting that post-translational modifications can be 
more widely involved in the regulation of NK cell activating ligands.
In the context of the innate immune response, a post-translational regulation of ligands for activating NK cell 
receptors could contribute to modulate very rapidly target cell susceptibility to NK cell recognition.
Of note, DNAM1 and NKG2D are not exclusively expressed on NK cells but are shared by other lympho-
cytes52, 53. Thus, post-translational modifications of their ligands, by preventing target cell recognition, may have 
a broader impact on anti-tumor immunity.
Collectively, our results shed light into the molecular mechanisms that regulate immune activating ligand expres-
sion. We reveal a previously undefined role for the SUMO pathway that could represent an attractive candidate for 
therapeutic intervention aimed at facilitating immune cell-mediated recognition and killing of tumor cells.
Figure 8. PVR expression is regulated by SUMO pathway in breast cancer and glioma cell lines. (a) 
MDAMB231 and U87MG cells were treated overnight with 25 μg/mL of GA or vehicle alone (DMSO), and 
then evaluated for PVR surface expression by immunofluorescence and FACS analysis with FACSCanto (BD 
Bioscience). Means ±SD from three independent experiments are shown. *p < 0.05, Student T test. (b) Primary 
cultured NK cells were pre-treated for 20 minutes at RT with anti-DNAM1 neutralizing mAb or with anti-CD56 
(Ctrl mAb) and were used as effector cells in a 4 hours 51Cr release assay toward GA or vehicle (DMSO)-treated 
MDAMB231 and U87MG cells. (c) PLA was performed on MDAMB231 breast cancer cells and U87MG glioma 
cells as in Fig. 4c. Images are representative of three independent experiments, and were acquired with zoom 2 
using 60X/1.35NA oil immersion objective. Z-projections of 30 slices are shown.
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Methods
Cell lines and clinical samples. The human MM cell lines SKO-007 (J3), U266, ARK, OPM-2, RPMI, LP1, 
and ARP were kindly provided by Prof. P. Trivedi (“Sapienza” University of Rome). The human breast cancer cell 
line MDA-MB-231 and the human glioma cell line U87MG were purchased by ATCC.
Cell line identity was verified by morphology, growth, immunophenotypic characteristics and biologic behav-
iour according to the provider recommendations, and periodically tested for mycoplasma contamination by 
EZ-PCR Mycoplasma Test Kit (Biological Industries, 20–700–20). All cell lines were kept in culture for less than 
two consecutive months. The cell lines were maintained at 37 °C in 5% CO2 in RPMI 1640 (Life Technologies) 
supplemented with 10% Fetal Calf Serum (FCS).
Primary cultured NK cells were obtained from 10-day co-cultures of PBMCs (4 × 105 cells/mL) with the irra-
diated EBV-transformed B-cell line RPMI 8866 (105 cells/mL) at 37 °C in 5% CO2 in the absence of IL-2, as pre-
viously described54.
Peripheral blood and bone marrow samples from patients with MM were managed at the Division of 
Hematology (“Sapienza” University of Rome). The study was conducted according to protocols approved by the 
Ethics Committee of “Sapienza” University of Rome (Rif. 3373) and informed consent, in accordance with the 
Declaration of Helsinki, was obtained from all patients.
MM bone marrow aspirates were cleared from red cells in a buffer containing 1.5 mol/L NH4Cl, 100 mmol/L 
NaHCO3 and 10 mmol/L ethylenediaminetetraacetic acid (EDTA). Bone marrow-derived mononuclear cells were 
maintained at 37 °C and 5% CO2 in complete medium supplemented with 20 ng/mL human recombinant IL-3 
(Pepro-Tech, 200–03) and 2 ng/mL human recombinant IL-6 (Pepro-Tech, 200–06), as previously described55.
In some experiments MM cells were purified using anti-CD138 magnetic beads (Miltenyi Biotec, 130–051–
301). More than 95% of purified cells expressed CD38 and CD138.
For experiments in which the SUMO pathway was inhibited, MM cells were cultured over-night at 37 °C in 
5% CO2 at the concentration of 2 × 106 cells/mL with different doses of Ginkgolic Acid (Calbiochem, 345887) 
or equal amounts of DMSO. A dose-response curve was constructed to identify the doses that did not affect cell 
viability and the dose of 25 μg/mL was chosen.
Virus production and in vitro transduction. pLKO.1-puro lentiviral vector expressing a short hairpin 
RNA targeting UBC9 was kindly provided by Dr. Shih (Academia Sinica, Taipei, Taiwan). The nontargeting con-
trol shRNA vector (pLKO.1) was purchased from Sigma-Aldrich. For lentivirus production, the Phoenix packag-
ing cell line HEK293 was transfected with 5 μg of viral DNA (pLKO.1 or pLKO.1-shUBC9) together with pVSVG 
and psPAX2 packaging vectors, using Lipofectamine 3000 (Life Technologies, L3000001). After transfection, cells 
were plated in fresh medium, and 48 hours later virus-containing supernatants were harvested, filtered and used 
immediately for two cycles of infections as follows: 2 mL viral supernatant in complete medium containing 8 μg/
ml Polybrene (Sigma-Aldrich, 107689) were used to infect 1 × 106 ARK or OPM2 cells for 2 hours. After 24 hours 
from the infection cells were selected with 1 μg/mL puromycin (Sigma Aldrich, P8833).
Immunofluorescence and FACS analysis. The identification of malignant PCs derived from bone mar-
row aspirates was performed by means of CD38-PE or CD38-APC (BD Biosciences, HIT2) and CD138-FITC (BD 
Biosciences, HI15). Surface ligands expression on patient-derived PCs was evaluated by means of PE-conjugated 
anti-PVR mAb (Biolegend, SKII.4), and APC-conjugated anti-Nectin2 mAb (R&D Systems, FAB2229A) after 
gating on the CD38+ CD138+ PC population. Cells were fixed and permeabilized with Fixation/Permeabilization 
kit (BD Biosciences) according to manufacturer’s instructions to evaluate total cellular proteins. The surface 
expression of DNAM1 ligands on MM cell lines was analysed by immunofluorescence staining using uncon-
jugated anti-PVR mAb (SKII.4, kindly provided by Prof. M. Colonna, Washington University, St. Louis, MO) 
followed by APC-conjugated goat anti-mouse (Jackson ImmunoResearch Laboratories, GAM-APC IgG), and 
APC-conjugated anti-Nectin2 (R&D Systems, FAB2229A). To evaluate total cellular proteins, MM cells were 
fixed with 2% paraformaldehyde (Sigma Aldrich, 158127) for 20 minutes at room temperature, permeabilized 
with 0.1% saponin (Sigma Aldrich, S7900) for 30 minutes at 4 °C, and washed with PBS 0.5% BSA before the 
staining. Samples were acquired using a FACSCalibur (BD Biosciences) in data shown in Figs 1b, 2b and c and 
Supplementary Figure S2, and FACSCanto (BD Biosciences) in all the other experiments.
The mean fluorescence intensity (MFI) subtracted from the MFI of the isotype control antibody was measured 
using FlowJo software (Ashland, OR).
Confocal microscopy and Proximity ligation assay (PLA). ARK cells were plated on 
poly-L-lysine-coated multichamber slides (LabTek, Thermo Scientific) and let adhere for 30 minutes at 37 °C. 
Cells were then fixed and permeabilized, as previously described54.
In experiments in which PVR expression was analysed cells were stained with the anti-PVR mAb 
(ThermoFisher Scientific, D171) followed by the AlexaFluor 488-conjugated goat anti-mouse IgG (Life 
Technologies). After extensive washing cells were counterstained with DAPI (Life Technologies, D1306) and 
coverslips were mounted using SlowFade gold reagent (Life Technologies, S36936).
Proximity Ligation Assay was performed using Duolink PLA In Situ Green Starter Kit (SigmaAldrich, Mouse/
Rabbit) according to manufacture’s instructions. Anti-PVR (ThermoFisher Scientific, D171) and anti-SUMO1 
(Enzo Life Sciences, BML-PW9460) were used as primary Abs.
High-resolution images (800 × 800 pixel, 8 μs/pixel) were acquired at room temperature using IX83 FV1200 
MPE laser-scanning confocal microscope with a 60 × /1.35 NA UPlanSAPO oil immersion objective (all from 
Olympus) as previously described56. Images were processed with Fiji ImageJ software. Were indicated, image 
stacks (40 slices of 0.5 μm z-step size) were acquired. Data quantification was performed with FiJi ImageJ software 
and 3D reconstructions were obtained with Imaris software v.8.1.2 (Bitplane).
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RNA isolation, RT-PCR and Real Time PCR. Total RNA was extracted using TRIzol (Life Technologies, 
AM9738), according to manufacturer’s instructions. Light absorbance at 260 nm (A260) and the ratio of A260/A280 
were measured to determine the concentration and quality of the extracted total RNA, respectively. One micro-
gram of total RNA was used for cDNA first strand synthesis in a 25 μL reaction volume according to the man-
ufacturer’s protocol for Moloney murine leukemia virus reverse transcriptase (Promega). Real-Time PCR was 
performed using the ABI Prism 7900 Sequence Detection system (Applied Biosystems). cDNAs were amplified in 
triplicate with primers for PVR (Hs00197846_m1) and GAPDH (Hs99999905_m1) both conjugated with fluoro-
crome FAM (Applied Biosystems). The level of ligand expression was measured using threshold cycle (Ct). The Ct 
was obtained by subtracting the Ct value of the gene of interest (PVR) from that of housekeeping gene (GAPDH). 
In the present study we used the Ct of the untreated sample or the mock-transfected one as the calibrator. The fold 
change was calculated as 2−ΔΔCt, where ΔΔCt is the difference between the Ct of the sample and the Ct of the 
calibrator (according to the formula the value of the calibrator in each run is 1). The analysis was performed using 
SDS version 2.2 software (Applied Biosystem).
Immunoprecipitation and Western blot analysis. Cells were lysed in a buffer containing 1% Triton 
X-100, 0,1% SDS, 50 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 0,5% sodium deoxycholate, 1 mmol/L EGTA, 
1 mmol/L EDTA, 5 mmol/L MgCl2, 1 mmol/L PMSF, 1 mmol/L Na3VO4, 5 mmol/L NaF pH 8, 20 mmol/L 
N-ethyl-malemide, 10 μg/mL of aprotinin and 5 μg/mL leupeptin, incubated 30 min on ice and then centrifugated 
at 13000 X g for 30 minutes at 4 °C and the supernatant was collected as whole-cell extract. Bio-Rad Protein Assay 
was used to determine protein concentration.
Immunoprecipitations was performed as previously described57 using anti-PVR (SKII.4) or control mouse 
IgG (Santa Cruz Biotechnology). Immunoprecipitates or total cell lysates were resolved by SDS-polyacrylamide 
gel (PAGE), proteins were then electro-blotted onto nitrocellulose membranes (Schleicher & Schuell, 
GEH10600002), and western blotting was performed as previously described57 with the following Abs: anti-PVR 
(S-18, Santa Cruz Biotechnology), anti-SUMO1 (Abcam, Y299), anti-UBC9 (BD Biosciences, 50/ubc9), anti-β 
actin (Sigma-Aldrich, AC-74). Fiji Image J software was used to perform densitometric analysis.
In vitro SUMOylation assay. A recombinant full-lenght human form of PVR (Abnova, H00005817) was 
used as substrate for in vitro SUMOylation. The reaction was carried out using 200 ng of the target protein in a 
20 μL reaction volume containing E1 and E2 enzymes involved in substrate SUMOylation, SUMO 1/2/3 proteins 
and SUMOylation buffer for 1 hour at 37 °C in the presence of ATP, according to manufacturer’s instructions 
(Enzo Life Sciences). Negative control reaction omitting Mg-ATP cofactors (required for E1 activation) was per-
formed. After in vitro SUMOylation samples were eluted with SDS-sample buffer and resolved by SDS/PAGE.
51Cr-release assay, degranulation assay, and conjugation assay. Primary cultured NK cells were 
pretreated with anti-DNAM1 (Serotec, DX11) or anti-CD56 (Serotec, NCAM16.2) Abs at 1 μg/106 cells for 
20 minutes at room temperature and employed as effectors cells in cytotoxicity or degranulation assays using as 
cell targets UBC9-silenced or mock-transfected ARK cells.
The 51Cr-release assay (4 hours) was used to measure cytotoxic activity against ARK target cells, as previously 
described54. Maximum release was assessed by incubating 51Cr-labeled target cells with 2.5% SDS, while spon-
taneous release was evaluated by incubating the target cells alone in culture medium. The percentage of specific 
lysis was determined as follows: ((mean cpm experimental release – mean cpm spontaneous release)/(mean cpm 
maximal release - mean cpm spontaneous release)) × 100. Lytic Units for 1 × 106 effector cells were calculated as 
previously described54.
Degranulation was determined by cell-surface expression of the lysosomal marker CD107a. Primary cultured 
NK cells and ARK cells were co-cultured at 2:1 E:T ratio in complete medium for 4 hours at 37 °C in the presence 
of CD107a-APC mAb (BD Biosciences, H4A3). After 1 hour, 50 μmol/L monensin (Sigma Aldrich, catalog num-
ber) was added. Cells were then stained with CD56-PE (BD Biosciences, NCAM16.2), CD3-FITC (Biolegend, 
OKT3) and CD138-PerCP-CY5.5 (BD Biosciences, MI15) to gate the CD56+ CD3− CD138− NK cell population 
and the analysis was performed with FACSCanto (BD Biosciences).
Degranulation of patient-derived NK cells was performed as previously described58 with some modifications. 
Briefly, as source of effector cells bone marrow purified NK cells cultured overnight with 200 U/mL IL-2 were 
used. Autologous patient-derived PC treated with GA or vehicle alone were used as target cells and were incu-
bated with effector cells at an E:T ratio of 2:1 in complete medium at 37 °C for 2 hours. At the end of the co-culture 
cells were washed with PBS 2% FCS 5 mmol/L EDTA, and stained with CD107a-APC, CD56-PE, CD3-FITC 
and CD138-PerCP-CY5.5 to gate the CD56+CD3−CD138− NK cell population. Analysis was performed using a 
FACSCanto (BD Biosciences).
For the conjugation assay primary cultured NK cells were labelled with CellTracker DeepRed (Life 
Technologies, C34565) while Mock or UBC9 silenced ARK cells were labelled with 2.5 μmol/L CFSE (Sigma 
Aldrich, 21888). Effector and target cells were spun at 100 g and left to interact for 30 minutes at 1:2 E:T ratio.
The percentage of conjugates was evaluated by FACSCanto (BD Biosciences) and calculated on red positive 
gated cells as follows: (red and green doublets/total red cells)x100.
Statistical analysis. Statistical significance between two groups was determined by performing two-tailed, 
paired Student’s t-test. Differences between multiple groups were analysed with two-way analysis of variance 
(ANOVA) using Šidák method for multiple comparisons. The non-parametric Wilcoxon matched-pairs signed 
rank test was used to analyse data coming from groups of patients. Prism 6 (GraphPad) software was used. Graphs 
show mean values, and all error bars represent the SD.
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Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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